Tim Anderson
Stock Analyst at B of A Securities
(4.43)
# 461
Out of 5,128 analysts
49
Total ratings
70.83%
Success rate
15.03%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Tim Anderson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JNJ Johnson & Johnson | Maintains: Neutral | $204 → $220 | $207.49 | +6.03% | 9 | Dec 15, 2025 | |
| LLY Eli Lilly and Company | Maintains: Buy | $1,286 → $1,268 | $1,108.09 | +14.43% | 2 | Dec 15, 2025 | |
| MRK Merck & Co. | Maintains: Buy | $105 → $120 | $108.60 | +10.50% | 5 | Dec 15, 2025 | |
| BMY Bristol-Myers Squibb Company | Upgrades: Buy | $52 → $61 | $56.72 | +7.55% | 2 | Dec 15, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Underperform | $543 → $627 | $812.27 | -22.81% | 3 | Oct 29, 2025 | |
| PFE Pfizer | Maintains: Neutral | $28 → $30 | $25.28 | +18.67% | 3 | Oct 3, 2025 | |
| AMGN Amgen | Maintains: Underperform | $261 → $272 | $341.64 | -20.38% | 6 | Sep 26, 2025 | |
| APGE Apogee Therapeutics | Maintains: Buy | $78 → $87 | $78.95 | +10.20% | 1 | Aug 28, 2025 | |
| AARD Aardvark Therapeutics | Maintains: Buy | $26 → $25 | $13.70 | +82.48% | 3 | Aug 28, 2025 | |
| ABBV AbbVie | Maintains: Neutral | $200 → $204 | $233.42 | -12.60% | 7 | Apr 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $116 → $126 | $124.35 | +1.33% | 3 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $41 → $34 | $35.89 | -5.27% | 2 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $178 | $186.91 | -4.77% | 1 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $141.98 | - | 1 | May 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $95.16 | - | 1 | Sep 22, 2017 |
Johnson & Johnson
Dec 15, 2025
Maintains: Neutral
Price Target: $204 → $220
Current: $207.49
Upside: +6.03%
Eli Lilly and Company
Dec 15, 2025
Maintains: Buy
Price Target: $1,286 → $1,268
Current: $1,108.09
Upside: +14.43%
Merck & Co.
Dec 15, 2025
Maintains: Buy
Price Target: $105 → $120
Current: $108.60
Upside: +10.50%
Bristol-Myers Squibb Company
Dec 15, 2025
Upgrades: Buy
Price Target: $52 → $61
Current: $56.72
Upside: +7.55%
Regeneron Pharmaceuticals
Oct 29, 2025
Maintains: Underperform
Price Target: $543 → $627
Current: $812.27
Upside: -22.81%
Pfizer
Oct 3, 2025
Maintains: Neutral
Price Target: $28 → $30
Current: $25.28
Upside: +18.67%
Amgen
Sep 26, 2025
Maintains: Underperform
Price Target: $261 → $272
Current: $341.64
Upside: -20.38%
Apogee Therapeutics
Aug 28, 2025
Maintains: Buy
Price Target: $78 → $87
Current: $78.95
Upside: +10.20%
Aardvark Therapeutics
Aug 28, 2025
Maintains: Buy
Price Target: $26 → $25
Current: $13.70
Upside: +82.48%
AbbVie
Apr 28, 2025
Maintains: Neutral
Price Target: $200 → $204
Current: $233.42
Upside: -12.60%
Mar 5, 2025
Maintains: Buy
Price Target: $116 → $126
Current: $124.35
Upside: +1.33%
Feb 11, 2025
Maintains: Underperform
Price Target: $41 → $34
Current: $35.89
Upside: -5.27%
Dec 10, 2024
Reinstates: Neutral
Price Target: $178
Current: $186.91
Upside: -4.77%
May 9, 2022
Downgrades: Peer Perform
Price Target: n/a
Current: $141.98
Upside: -
Sep 22, 2017
Upgrades: Outperform
Price Target: n/a
Current: $95.16
Upside: -